DYN · Dyne Therapeutics, Inc.

Track DYN — free

$25.17 +0.07 (+0.28%)

Russell 2000 member Rebalance outlook locked

Market Cap

$4.66B

186.75M

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Jul 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$73.19M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-10.3%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$476.79M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.9%

Year over year · more shares

Price change (1Y)

+86.1%

Trailing year

Short interest

11.5%

Latest settlement · 11.0 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.67

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +27%

above

Price vs 50-day avg +2%

above

RSI (14) 47

neutral

MACD trend Negative

52-week position 88%

near high

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Strong

1-month return −3%

trailing

6-month return +26%

trailing

YTD return +28%

this year

Relative strength +13%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $24 › 200d $20 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +49 funds added

Insider flow Distributing

Net -$14.2K over 90 days · 50% sells

Short interest Falling

11.49% of float · ▼ -2.3% MoM · 11.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

247 holders — near 3-yr high, broad support

Squeeze score 72

high risk · 0–100

Fundamentals

Weak

EPS growth −3%

Y/Y

Free cash flow $-405.1M

Balance sheet $744.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 77%

annualized · 1-yr

Max drawdown −40%

past year

ATR 4.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+27% Bullish

Price vs 50-day avg

+2% Bullish

RSI (14)

47 Neutral

MACD trend

Negative Bearish

52-week position

88% Bullish

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $24 › 200d $20 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +49 funds added

Insider flow Distributing

Net -$14.2K over 90 days · 50% sells

Short interest Falling

11.49% of float · ▼ -2.3% MoM · 11.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

247 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $12 Now $25 · 88% Range high $27

vs 200-day avg +27% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
DYN Dyne Therapeutics, Inc. this stock	$4.66B	+28.3%	—	—	11.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$137.30B	+20.8%	+46.2%	31.6	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$84.82B	+6.7%	+20.8%	20.4	2.3%
ARGX Argenx SE	$64.16B	+22.3%	—	—	1.9%
MRNA Moderna, Inc.	$61.59B	+423.1%	+4.3%	—	13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

247

% held: 102.2%
Net QoQ: +2.7M sh
Top holder: T. Rowe Price Investment…

Held Float

View

Held by Funds

Fund positions

240

View

Short & Settlement

Short Interest Falling

Shares short

21.5M

Days to cover: 11.0d
Change: -510.7K sh

View

Short Volume

Short vol %

46%

As of: Sep 1, 2026

Short Total

View

Fails to Deliver

FTD shares

55.5K

Value: $1.4M
As of: Jul 31, 2026

View

Off-Exchange

Off-exchange %

40.1%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$14.2K

Buyers / Sellers: 1 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-446

EPS diluted: $-3.47

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 29, 2026
This year: 15

View

Proposed Sales

Value

$131.0K

Shares: 5.0K
Filed: Aug 13, 2026

View

Exempt Offerings

Offering

$115.7M

Filed: Aug 14, 2020

View

Earnings & Events

Earnings Calls

Last call

Jun 3, 2026

View

Performance

	5D	20D	120D	MTD	YTD
DYN	-4.7%	-3.4%	+25.6%	-1.3%	+28.3%
SPY	-0.5%	-1.2%	+12.6%	-0.7%	+11.7%
vs SPY	-4.2%	-2.1%	+12.9%	-0.6%	+16.6%

Key facts CIK 1818794 CUSIP 26818M108 13F (30d) 211 filings 209 filers Visit website Investor relations

DYN · Dyne Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance